Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Candesartan Cilexetil

FDA-approved product (tablet, oral), marketed as Atacand, Candesartan Cilexetil.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Candesartan Cilexetil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angina pectoris
  • Congestive heart failure
  • Diabetes mellitus
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Angiotensin ii receptor blockers (arbs), plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Candesartan Cilexetil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Candesartan Cilexetil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment

    NCT00741585 · start 2008-09-01

    Registered record
    Registry ID
    NCT00741585
    Conditions
    Essential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease
    Interventions
    Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoring
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09-01
    Completion
    2018-06-30
    Enrolment
    21,983

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease
    InterventionAny antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoring
    PhasePhase 4
    Registry statusCompleted

  • Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension

    NCT00644475 · start 2008-03

    Registered record
    Registry ID
    NCT00644475
    Conditions
    Essential Hypertension
    Interventions
    Imidapril; Candesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2008-03
    Completion
    2009-03
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionImidapril; Candesartan
    PhasePhase 3
    Registry statusUnknown

  • A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients

    NCT00538486 · start 2008-02

    Registered record
    Registry ID
    NCT00538486
    Conditions
    Hypertension; Obesity
    Interventions
    Telmisartan plus Metformin; Telmisartan; Candesartan; Candesartan plus Metformin; Amlodipine; Amlodipine plus Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-02
    Completion
    2009-06
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Obesity
    InterventionTelmisartan plus Metformin; Telmisartan; Candesartan; Candesartan plus Metformin +2 more
    PhasePhase 4
    Registry statusCompleted

  • CCB Safety Study in Treatment of Hypertension of ADPKD

    NCT00541853 · start 2007-12

    Registered record
    Registry ID
    NCT00541853
    Conditions
    Kidney, Polycystic, Autosomal Dominant
    Interventions
    Candesartan; Candesartan and Cilnidipine; Candesartan plus non-CCB agents
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2007-12
    Completion
    2012-11
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney, Polycystic, Autosomal Dominant
    InterventionCandesartan; Candesartan and Cilnidipine; Candesartan plus non-CCB agents
    PhasePhase 4
    Registry statusUnknown

  • Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients

    NCT00573742 · start 2007-09

    Registered record
    Registry ID
    NCT00573742
    Conditions
    Primary Hypertension
    Interventions
    Candesartan Cilexeotil 16mg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-09
    Completion
    2008-02
    Enrolment
    1,940

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Hypertension
    InterventionCandesartan Cilexeotil 16mg
    PhaseNot recorded
    Registry statusCompleted

  • Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)

    NCT00690612 · start 2007-09

    Registered record
    Registry ID
    NCT00690612
    Conditions
    Hypertension
    Interventions
    candesartan cilexetil
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-09
    Completion
    2009-09
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventioncandesartan cilexetil
    PhasePhase 3
    Registry statusCompleted

  • Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity

    NCT00459771 · start 2007-06

    Registered record
    Registry ID
    NCT00459771
    Conditions
    Breast Cancer
    Interventions
    AT1 blocker candesartan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-06
    Completion
    2014-12
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionAT1 blocker candesartan; Placebo
    PhasePhase 3
    Registry statusCompleted

  • COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus

    NCT00526279 · start 2007-06

    Registered record
    Registry ID
    NCT00526279
    Conditions
    Hypertension
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-06
    Completion
    2008-08
    Enrolment
    9,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH

    NCT00607633 · start 2007-01

    Registered record
    Registry ID
    NCT00607633
    Conditions
    Essential Hypertension; Left Ventricular Hypertrophy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-01
    Completion
    2007-10
    Enrolment
    686

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension; Left Ventricular Hypertrophy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide

    NCT00360178 · start 2006-07

    Registered record
    Registry ID
    NCT00360178
    Conditions
    Hypertension
    Interventions
    Valsartan plus Hydrochlorothiazide; Candesartan plus Hydrochlorothiazide; Amlodipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-07
    Completion
    2006-12
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionValsartan plus Hydrochlorothiazide; Candesartan plus Hydrochlorothiazide; Amlodipine
    PhasePhase 3
    Registry statusCompleted

  • Effects of Sodium Intake on (PK/PD) Relationship of a Single Dose of a Renin Angiotensin System-Blocker

    NCT00310778 · start 2006-03

    Registered record
    Registry ID
    NCT00310778
    Conditions
    Healthy
    Interventions
    high sodium diet; low sodium diet; ramipril 10 mg; valsartan 160 mg; candesartan 8 mg; atenolol 50 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-03
    Completion
    2007-03
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionhigh sodium diet; low sodium diet; ramipril 10 mg; valsartan 160 mg +2 more
    PhasePhase 1
    Registry statusCompleted

  • Effect of Angiotensin II Receptor Blockers (ARB) on Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis

    NCT00294775 · start 2006-02

    Registered record
    Registry ID
    NCT00294775
    Conditions
    Aortic Valve Stenosis; Left Ventricular Hypertrophy; Atrial Fibrillation
    Interventions
    Candesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2006-02
    Completion
    2009-06
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAortic Valve Stenosis; Left Ventricular Hypertrophy; Atrial Fibrillation
    InterventionCandesartan
    PhasePhase 3
    Registry statusUnknown

  • Investigation of Vascular Relaxing Effects of Candesartan and Pioglitazone.

    NCT00154037 · start 2005-10

    Registered record
    Registry ID
    NCT00154037
    Conditions
    Healthy Subjects
    Interventions
    Pioglitazone (drug) and/or candesartan (drug)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-10
    Completion
    2006-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionPioglitazone (drug) and/or candesartan (drug)
    PhaseNot applicable
    Registry statusCompleted

  • The Canadian Prevention of Renal and Cardiovascular Endpoints Trial

    NCT00231803 · start 2005-04

    Registered record
    Registry ID
    NCT00231803
    Conditions
    Chronic Kidney Disease
    Interventions
    Combined CKD and CVD Prevention; Cardiovascular Disease prevention; Treatment of Chronic Kidney Disease complications; Usual care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-04
    Completion
    2008-06
    Enrolment
    474

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease
    InterventionCombined CKD and CVD Prevention; Cardiovascular Disease prevention; Treatment of Chronic Kidney Disease complications; Usual care
    PhaseNot applicable
    Registry statusCompleted

  • Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)

    NCT00108706 · start 2004-12

    Registered record
    Registry ID
    NCT00108706
    Conditions
    Cerebrovascular Accident; Acute Stroke
    Interventions
    Candesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2004-12
    Completion
    2007-09
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebrovascular Accident; Acute Stroke
    InterventionCandesartan
    PhasePhase 4
    Registry statusUnknown